Company Announcement – Issue 38 / 2024
Zealand Pharma Major Shareholder Announcement: Van Herk Investments
Copenhagen, Denmark, June 28, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that on 28 June 2024 it received notices pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As of June 28, 2024, Van Herk Investments BV (Dutch registration number 59055057) holds 6,874,960 nominal shares in Zealand Pharma A/S (1 vote per share), representing 9.68% of Zealand Pharma A/S’s total share capital and total voting rights.
Van Herk Investments BV is 100% owned by Van Herk Investments THI BV, which is 100% owned by Van Herk Private Equity Investments BV (Dutch registration number 58894543), which is ultimately owned and controlled by Mr Adrianus van Herk.
Van Herk Management Services BV (Dutch registration number 24377325) manages and exercises voting rights on behalf of Van Herk Investments BV and accordingly Van Herk Management Services BV manages and exercises voting rights of a nominal 6,874,960 shares (1 vote per share), representing 9.68% of the total share capital and total voting rights of Zealand Pharma A/S.
Van Herk Management Services BV is controlled by OGBB A. van Herk BV (Dutch registration number 24160906), OGBB A. van Herk BV is controlled by A. van Herk Holding BV (Dutch registration number 24160780), A. van Herk Holding BV is ultimately controlled by Mr Adrianus van Herk.
Please see the attached notification form for further details.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of peptide-based pharmaceuticals. Zealand has invented more than ten drug candidates that have advanced into clinical development, two of which have been introduced to the market and three are in late stage development. The Company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products.
Founded in 1998 and headquartered in Copenhagen, Denmark, Zeanland also has a team in the U.S. More information on Zeanland’s business and activities can be found here. http://www.zealandpharma.com.
contact:
|
Adam Lange (Investor) |
|
Investor Relations |
|
Zealand Pharma |
|
inquiry |
|
Dr. Anna Krasovska (Investors and Media) |
|
Vice President, Investor Relations and Corporate Communications |
|
Zealand Pharma |
|
akrassowska@zealandpharma.com |
Attachments
